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Abstract. In recent years an extensive series of synthetic 
combretastatin A-4 (CA-4)-azetidinone (β-lactam) hybrids 
were designed and synthesised with a view to improve the 
stability, therapeutic efficacy and aqueous solubility of CA-4. 
Lead compounds containing a 3,4,5-trimethoxy aromatic ring 
at position 1 and a variety of substitution patterns at positions 3 
and 4 of the β-lactam ring were screened in three adenocarci-
noma-derived colon cancer cell lines (CT-26, Caco-2 and the 
CA-4 resistant cell line, HT-29). In both CT-26 and Caco-2 
cells all β-lactam analogues analysed displayed potent thera-
peutic efficacy within the nanomolar range. Substitution of 
the ethylene bridge of CA-4 with the β-lactam ring together 
with the aforementioned aryl substitutions improved the thera-
peutic efficacy of CA-4 up to 300-fold in the combretastatin 
refractory HT-29 cells. The lead compound combretazet-3 
(CAZ-3); chemical name [4-(3-hydroxy-4-methoxyphenyl)-3-
(4-hydroxyphenyl)-1-(3,4,5-trimethoxyphenyl)azetidin-2-one] 
demonstrated improved chemical stability together with 
enhanced therapeutic efficacy as compared with CA-4 
whilst maintaining the natural biological properties of CA-4. 
Furthermore, CAZ-3 demonstrated significant tumour inhibi-
tion in a murine model of colon cancer. Our results suggest 
that combretastatin-azetidinone hybrids represent an effective 
novel therapy for the treatment of combretastatin resistant 
carcinomas.
Introduction
Microtubules are a principle component of the cytoskeleton 
and play a key role in numerous biological functions including 
cell division and organelle transport. The pivotal role of tubulin 
in both the formation of the mitotic spindle and chromosomal 
separation promoted the surge in the development of both 
natural and synthetic microtubule targeting agents (MTAs). 
One such naturally occurring drug, combretastatin A-4 (CA-4; 
Fig. 1) was originally described by Pettit et al (1). The structure 
of CA-4 proved readily amenable to chemical manipulation 
to improve the stability, solubility and therapeutic index of 
this class of MTAs. Over the past two decades a vast array 
of synthetic CA-4 analogues were designed and synthesised 
with many surpassing the stability, solubility and therapeutic 
efficacy of the parent compound (2). The clinical success of 
the synthetic prodrug of CA-4, combretastatin-A4 phosphate 
(CA-4P) in the treatment of anaplastic thyroid carcinoma 
(www.clinicaltrials.gov) (3) has maintained an active interest 
in the chemical manipulation of CA-4 with the view to further 
enhancing the therapeutic efficacy of this lead compound. 
Furthermore, amino acid containing prodrugs of CA-4 are 
also undergoing clinical evaluation including AVE8062 (www.
clinicaltrials.gov) (4). Structural modifications of CA-4 can be 
divided into three areas, those involving the manipulation of 
either ring A, ring B or those involving the substitution of the 
double bond (ethylene bridge structure) connecting both rings 
(Fig. 1). These A and B substituted aromatic rings fit into the 
A and B pockets of the colchicine binding site on tubulin. Data 
collated from numerous structural activity relationship (SAR) 
studies confirm that a non-planar cis conformation is essential 
for the tubulin binding properties of CA-4. Furthermore, the 
majority of studies suggest that the 3,4,5-trimethoxy-substituted 
aromatic A-ring should be conserved to maintain maximum 
anticancer activity. However, contrary to this, a recent study 
conducted by Beale et al (5) showed that substitution of the 
larger meta-methoxy groups of triazole CA-4 derivatives 
with smaller halogen atoms yielded more potent CA-4/CA-1 
analogues. Several independent studies have demonstrated 
that the therapeutic activity of CA-4 can also be enhanced by 
the strategic modification of ring B (6). Apart from strategies 
to improve the potency of CA-4 other main areas of research 
focused on methods to overcome the solubility issues of CA-4 
and also to prevent the undesired conversion into the inactive 
trans isomer (Fig. 1). Modification of the phenolic group on 
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ring B forming either a phosphate or an amino acid ester was 
demonstrated to be an effective method of improving the solu-
bility of CA-4 whilst retaining optimum biological activity. 
Double bond isomerisation can be prevented by the strategic 
inclusion of various types of heterocyclic rings in place of the 
usual ethylene bridge structure of CA-4 (7).
In recent years our group has designed and synthesised 
an extensive series of azetidinone (β-lactam) CA-4 analogues 
with a view to overcoming double bond isomerisation by 
substituting the ethylene bridge structure for a 1,4-diaryl-
2-azetidinone ring. The rigid β-lactam ring scaffold allows a 
similar spatial arrangement between the two aromatic rings as 
observed in the non-planar cis-conformation of CA-4 while 
permanently preventing the undesired conversion to the inac-
tive trans-configuration (8). Further studies demonstrated that 
the inclusion of an aromatic ring at position 3 of the β-lactam 
significantly improved the potency of the series. Hence, a 
β-lactam substituted at position 3 with a phenolic ring soon 
became the core structure for future designs (9). Solubility 
issues of the CA-4-azetidinone analogues were addressed by 
esterification of the 3'OH group of ring B with phosphates and 
amino acids (unpublished data).
However, despite the significant advances made in recent 
years in terms of improving the solubility and stability of 
CA-4, the lack of therapeutic efficacy as a single agent and the 
emergence of resistance to CA-4 has somewhat hindered the 
clinical and commercial success of this compound. We recently 
reported that CA-432, a lead combretastatin-azetidinone 
hybrid was 10-fold more potent than CA-4 in CA-4 refractory 
HT-29 cells, suggesting a possible functional advantage of the 
ethylene bridge-azetidinone substitution (10). In this study, we 
screened selected combretastatin-azetidinone hybrids (here-
after referred to as combretazets) to further characterise the 
structure activity relationship of these compounds in the CA-4 
resistant HT-29 cells. The stability and therapeutic potential of 
a lead compound combretazet-3 (CAZ-3) as a single agent in 
the murine CT-26 colon cancer model was evaluated.
Materials and methods
Compounds. CA-4 and bafilomycin A1 were purchased from 
Sigma-Aldrich (Poole, Dorset, UK). 1,4-Diaryl-2-azetidinone 
analogues were synthesised as previously described by Carr 
et al (8) CAZ-1, CAZ-2 and CAZ-3 (9), CAZ-4 (7), CAZ-5 
(11), CAZ-2P, CAZ-3P, CAZ-4P, CAZ-6 and CAZ-7 (unpub-
lished data). All general reagents unless stated otherwise 
were purchased from Sigma. Bafilomycin A1 was dissolved 
in DMSO. CA-4 and all analogues were prepared as a 10-mM 
stock in ethanol and stored at -20˚C.
Cell culture. CT-26 cells are a chemically (N-nitroso-N-
methylurethane) induced, undifferentiated murine colon 
carcinoma fibroblast cell line originating from BALB/c mice. 
HT-29 and Caco-2 cells originate from a human adenocarci-
noma of the colon and were originally obtained from the 
European Collection of Cell Cultures. All cells were grown 
in DMEM Glutamax media. CT-26 and HT-29 media were 
supplemented with 10% foetal bovine serum (FBS) and 
Caco-2 were cultivated with 20% FBS. Both CT-26 and 
Caco-2 media were supplemented with 1% non-essential 
amino acids (NEAA). All media contained 100 U/ml peni-
cillin and 100 µg/ml streptomycin. Cells were maintained 
at 37˚C in 5% CO2 in a humidified incubator. Cell culture 
materials were supplied from Gibco, Invitrogen Corp. (Grand 
Island, NY, USA). All cells were sub-cultured 3 times/week 
by trypsinisation.
Alamar blue cell viability assay. Cell proliferation was analysed 
using the Alamar Blue assay (Invitrogen Corp.) according to 
the manufacturer's instructions. Cells were seeded at a density 
of 5x103 cells/well (CT-26) or 1x104 cells/well (Caco-2, HT-29) 
in triplicate in 96-well plates. After 24 h, cells were then treated 
with either medium alone, vehicle [1% ethanol (v/v)] or with 
serial dilutions of CA-4 or combretazets. After 72 h, Alamar 
Blue [10% (v/v)] was added to each well and plates were incu-
bated for 3-5 h at 37˚C in the dark. Fluorescence was read using 
a 96-well fluorimeter with excitation at 530 nm and emission 
at 590 nm. Results were expressed as percentage viability 
relative to vehicle control (100%). Dose response curves were 
plotted and IC50 values (concentration of drug resulting in 50% 
reduction in cell survival) were obtained using the commercial 
software package Prism (GraphPad Software, Inc., La Jolla, 
CA, USA). Experiments were performed in triplicate on at 
least three separate occasions.
Cell cycle detection. After treatment, cells were collected then 
centrifuged at 800 x g for 10 min and fixed with 70% ethanol 
overnight at -20˚C. The ethanol was removed by centrifugation 
at 800 x g for 10 min. The cells were then stained in PBS 
containing 0.5 mg/ml RNase A and 0.15 mg/ml propidium 
iodide and then incubated for 30 min in the dark at 37˚C. Cell 
cycle distribution was analysed by flow cytometry at 488 nm 
using the FACSCalibur flow cytometer (Becton-Dickinson, 
San Jose, CA). All data were recorded and analysed using the 
CellQuest Software (Becton-Dickinson).
Plasma and pH stability studies. Peripheral blood was 
collected from healthy donors with informed consent and 
was made anonymous prior to use. The plasma was separated 
by Ficoll-gradient and diluted (1:9) with PBS pH 7.4 and 
warmed to 37˚C. The pH stability study was carried out in 
PBS pH 3.0. Test compounds (1.5 mg/ml) were dissolved 
in acetonitrile at time t=0. Plasma solution containing test 
compound (250 µl) was added to 2% (w/v) ZnSO4 solution 
in acetonitrile: water (1:1) (500 µl). Aliquots were taken at 
the specified time intervals, vortexed, centrifuged for 3 min 
at 9,500 x g before injection onto an HPLC column (Varian 
Pursuit XRs C18 reverse phase 250x4.6 mm chromato graphy 
column) to determine the stability using a Waters 2487 
Dual Wavelength Absorbance Detector, a Waters 1525 
Binary HPLC Pump, a Waters In-Line Degasser AF and a 
Waters 717 plus Autosampler. Samples were detected using 
a wavelength of 254 nm. All samples were analysed using 
acetonitrile (60%):water (40%) with 0.1% (v/v) trifluoroacetic 
acid over 10 min and a flow rate of 1 ml/min to evaluate the 
percentage decline in the predetermined peak area for each 
compound. The retention times for CA-4 and CAZ-3 were 
5.9 and 3.7 min, respectively. The percentage recovery was 
calculated using the following formula [(plasma or pH 3.0 
peak area/mean aqueous peak area) x 100].
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Human microsomal stability study. Microsomal stability 
was determined using pooled human liver microsomes (The 
UK Human Tissue Bank, Leicester, UK). Ethical approval 
was obtained from south Cheshire Local Research Ethics 
Committee (Chester, UK). Test compound (3 µM) together 
with microsome protein (0.5 mg/ml), 1 mM NADPH in 0.1 M 
phosphate buffer pH 7.4 was incubated for 0, 5, 15, 30 and 
45 min. The negative control did not contain NADPH. The 
samples were quenched with methanol and the protein was 
precipitated by centrifugation for 20 min at 1,100 x g at 4˚C. 
Supernatants were then analysed by LC/MS. The In peak 
area ratio (compound peak area/internal standard peak area) 
was plotted against time and the slope of the line deter-
mined to give the elimination rate constant [K = (-1) (slope)]. 
The half life (t1/2) and the in vitro intrinsic clearance (CLint 
µl/min/mg protein) were calculated by the following equa-
tions; t1/2 = 0.693/K; CLint = V (0.693)/t1/2 where V, incubation 
volume in µl/mg microsomal protein.
Quantification of AVOs with acridine orange staining using 
flow cytometry. Autophagy is characterised by the formation 
and promotion of acidic vesicular organelles (AVOs). The 
formation of acidic compartments was quantified by flow cyto-
metric analysis of acridine orange stained cells (10). Acridine 
orange stains the cytoplasm green and the nucleus a dim red, 
whereas acidic compartments fluoresce bright red. The inten-
sity of the red fluorescence is proportional to the amount of 
acidity. Following treatment, cells were stained with acridine 
orange 1 µg/ml for 15 min at 37˚C. Bafilomycin A1 (5 nM) was 
dissolved in DMSO and added to the cells 45 min prior to the 
addition of acridine orange. Cells were then trypsinised and 
collected in phenol-red free medium. Green (510-530 nm) and 
red (650 nm) fluorescence emission from 104 cells illuminated 
with blue (488 nm) excitation light was measured with a CyAn 
ADP Flow Cytometry Analyzer (Beckman Coulter, Nyon, 
Switzerland). The red:green fluorescence ratio for individual 
cells was calculated using FlowJo software (Tree Star, Inc., 
San Carlos, CA).
In vivo studies. Tumour growth was initiated by subcutaneous 
injection of a CT-26 cell suspension (106 cells) into the right 
flank of 6-8 week old female Balb/c mice. The experiments 
were conducted on Day 7 when tumours reached a maximum 
diameter range of 3.6-6.3 mm. Mice were randomly divided 
into two groups of five. The treatment group received a single 
intraperitoneal (i.p.) injection of 40 mg/kg CAZ-3 dissolved in 
ethanol:cremophore:PBS [10%:10%:80% (v/v)] and the control 
group received one i.p. injection of vehicle only. Tumour 
growth was measured every second day with a sterile vernier 
callipers. The long (L) and short (S) axes were recorded and 
tumour volume (V) was calculated using the following equa-
tion V = (S2xL)/2. Mice were culled by CO2 asphyxiation at the 
experimental end point. Ethical approval was obtained from 
the Research Ethical Approval Committee, Trinity College 
Dublin. The study was performed under the license number: 
B100/4275 granted by Department of Health and Children, 
Hawkins House, Dublin 2, Ireland.
Results
The effects of CA-4 and selected combretazets on the viability 
of colon cancer-derived cell lines. The synthetic combretazets 
were designed and synthesised with a view to improve the 
stability, therapeutic efficacy and aqueous solubility of the 
parent compound CA-4, hence many in the series contained 
a phenolic group, phosphate ester or an amino group (Fig. 1). 
Figure 1. Structures and nomenclature of combretastatin-A4 and selected combretazets.
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All combretazets analysed were effective in the nanomolar 
range in drug-sensitive CT-26 and Caco-2 cells and were more 
potent than CA-4 in CA-4 refractory HT-29 cells (Table I). 
Compound CAZ-2 is identical to CA-4 with the exception of 
the azetidinone-ethylene bridge substitution and demonstrated 
an 8-fold increase in activity in HT-29 cells confirming a 
functional advantage of the ethylene bridge-azetidinone substi-
tution in overcoming combretastatin resistance. Compounds 
containing a B-ring meta-hydroxy group (CAZ-1, CAZ-2 
and CAZ-4) or a phosphate (CAZ-2P, CAZ-3P and CAZ-4P) 
conjugate were the least active of the series in the combreta-
statin refractory HT-29 cells. Deletion (CAZ-5) or substitution 
of the B-ring meta-hydroxy group with an amine conjugated 
amino acid (CAZ-6 and CAZ-7) significantly increased 
activity of the series with IC50 values in the nanomolar range 
in combretastatin refractory HT-29 cells. However, CAZ-3 
with a B-ring meta-hydroxy group was the exception to this 
observation. CAZ-3 was more potent than CA-4 in all three 
adenocarcinoma-derived cell lines tested. Hence, CAZ-3 was 
selected for further biological analysis.
The effects of CA-4 and selected combretazets on the cell cycle 
in CT-26 cells. CT-26 cells were selected for further analysis 
given that all combretazets were effective in the nanomolar 
range in this cell line. The effects of CA-4, CAZ-3 and its 
corresponding prodrug CAZ-3P on the cell cycle and cell 
death were assessed by flow cytometric analysis of propidium 
iodide stained CT-26 cells. The percentage of cell death was 
estimated by the quantification of the pre-G1 peak. As shown 
in Fig. 2, all compounds tested produced an early G2M cell 
cycle arrest at 8 h followed by a significant time-dependent 
increase in cell death.
Induction of autophagy by CAZ-3. Our recent findings demon-
strated that CA-4 and CAZ-2 (CA-432) induced autophagy in 
adenocarcinoma-derived colon cells as confirmed by acridine 
orange staining of vesicle formation, electron microscopy 
and increased expression of LC3-II (10). Hence, the effect of 
Table I. Evaluation of CA-4 and selected combretazets in adenocarcinoma-derived colon cancer cells.
 CT-26 Caco-2 HT-29 -------------------------------------------------- -------------------------------------------------- ------------------------------------------------------
Compound IC50 (nM) RI IC50 (nM) RI IC50 (nM) RI
CA-4 5.7  1.0 41.2  1.0 9020   1.0
CAZ-1 11.8 -2.1 236.0 -5.7 1011 +8.1
CAZ-2 13.46 -2.4 113.6 -2.8 909 +9 (11)
CAZ-3 4.25 +1.4 15.3 +5.6 50 +180.0
CAZ-4 165.0 -28.9 28.3 +1.5 3510 +2.6
CAZ-5 136.9 -24.1 ND ND 30 +300.0
CAZ-6 118.0 -20.7 120.7 -2.9 70 +128.9
CAZ-7 245.3 -43.0 704.2 -17.1 260 +34.7
CAZ-2P 75.17 -13.2 96.7 -2.4 440 +20.5
CAZ-3P 8.0 -1.4 109.3 -2.7 119 +7.6
CAZ-4P 9.7 -1.7 ND ND 4670 +1.93
Cells were exposed to multiple concentrations of the indicated compound for 72 h. Cell viability was assessed using the Alamar Blue assay 
and respective IC50 values were calculated. ND, not determined. RI, relative inhibition, compared to CA-4. The most active analogue, CAZ-3, 
is highlighted in bold.
Table II. Calculation of intrinsic clearance values (CLint) for 
CA-4 and CAZ-3 in human microsomes.
Compound CLint (µl/min/mg protein) t1/2 (min)
CA-4 157.0±18.9   8.83
CAZ-3   76.7±21.4 18.1
Compounds (3 µM) were incubated in the presence of NADPH 
(1 mM) and human liver microsomes (0.5 mg/ml) and intrinsic 
clearance values were calculated as described in Materials and 
methods. Clearance values are expressed as (µl/min/mg) of micro-
somal protein. Values represent the mean ± SEM of at least triplicate 
determinations.
Table III. Suppression of tumour growth by CAZ-3.
 Tumour volume Tumour volume
Group (Day 7) (Day 11) Mortality
Control 37.08±8.326 263.2±62.13 0/5
CAZ-3 42.45±11.45 77.62±19.24 1/5
Single IP NS <0.05a
40 mg/kg
BALB/c mice (n=10) were inoculated subcutaneously with 106 CT-26 
cells. On Day 7 mice received a single i.p. injection of vehicle 
(ethanol:cremophore:PBS; 10%:10%:80%) or 40 mg/kg CAZ-3. 
Tumour growth was measured every second day using a sterile 
vernier callipers. Values represent the mean ± SEM (Student's t-test; 
aP<0.05; NS, not significant).
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CAZ-3 on autophagic vesicle formation was evaluated by flow 
cytometric analysis of acridine orange stained cells. Fig. 3 
indicates that like other combretastatins CAZ-3 also induced 
autophagy in adenocarcinoma cells. Furthermore, CAZ-3 also 
induced autophagy in HT-29 and Caco-2 adenocarcinoma-
derived colon cancer cells (data not shown). Numerous studies 
have demonstrated a dependence of the acidification of cellular 
organelles on the vacuolar H+ ATPase using the specific inhi-
bitor bafilomycin A1. Similarly, pretreatment of CT-26 cells 
with bafilomycin A1 significantly inhibited CAZ-3 induced 
autophagy (Fig. 3).
CAZ-3 is more stable than CA-4 in both human plasma and 
microsomes. The stability of CA-4 and CAZ-3 in acidic media 
and in human plasma was next determined by HPLC. Both 
compounds were stable in plasma at physiological pH 7.3 
for up to 5 h (Fig. 4A) and remained stable up to 24 h (data 
not shown). Under acidic conditions (pH 3.0) CAZ-3 is more 
stable than CA-4 (Fig. 4B). These findings are in agreement 
with other studies demonstrating instability of CA-4 in acidic 
media (12). Microsome stability was determined using pooled 
human liver microsomes (Table II). The β-lactam bridge 
improved the metabolic stability of CAZ-3 as compared with 
CA-4 by doubling the in vitro clearance time.
CAZ-3 significantly inhibited the growth of CT-26 cells grafted 
to mice. To study the effects of CAZ-3 on tumour growth we 
selected the CT-26 murine model of colon carcinoma, a model 
frequently used to test the efficacy of CA-4 and its synthetic 
analogues (13). Furthermore, experimental models involving 
xenografts of human tumours in a mouse host may lack some of 
the critical tumour host interactions. In the antitumour efficacy 
experiment mice received a single IP injection of 40 mg/kg 
on Day 7 when tumours were on average 5 mm in diameter. 
On Day 7 there was no significant difference between control 
and CAZ-3 treated groups. By Days 9 (data not shown) and 
Figure 2. CAZ-3 and its prodrug CAZ-3P induce G2M cell cycle arrest and cell death in a similar manner to CA-4 in murine CT-26 adenocarcinoma cells. 
CT-26 cells were treated with vehicle [ethanol 0.2% (v/v)] or 50 nM of compound for the times indicated. Cells were then fixed, stained with PI and analysed 
by flow cytometry. The percentage of cell death was determined by quantification of the sub-G1 peak. Values represent the mean ± SEM for three independent 
experiments (Student's t-test: *P<0.05, **P<0.01).
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11 (Table III), CAZ-3 significantly inhibited tumour growth. 
Both a rough coat and diarrhoea were observed in 100% of 
CAZ-3 treated mice.
Discussion
Several water soluble CA-4 analogues including CA-4P 
(ZYBRESTAT), CA-1P (OXi4503) and AC7700 (AVE 8062) 
are currently undergoing clinical trials as vascular targeting 
agents (www.clinicaltrials.gov) (14,15). However, these 
compounds all contain the isomerisable olefinic bond which 
may hinder the continued clinical success of the compounds. 
To date there is no cis-stable CA-4 analogue undergoing 
clinical trials and hence there is a demand for pre-clinical data 
on potent cis-restricted CA-4 analogues. The combretazets 
are a novel class of synthetic combretastatin and azetidinone 
(β-lactam) hybrids that function through a combretastatin-like 
mechanism. Overall the combretastatins and the combretazets 
are structurally and functionally similar. Both classes exhibit 
a similar spatial arrangement between the two phenyl A and B 
rings but differ in the bridge structure connecting the rings. The 
strategic ethylene bridge-azetidinone substitution produced 
cis-stable analogues with improved chemical stability and ease 
of synthesis. Extensive biochemical analysis demonstrated that 
the ethylene bridge-azetidinone substitution did not influence 
the biological properties of CA-4 (9,10,16,17). In more detail, 
both classes of drugs inhibit the polymerisation of tubulin 
inducing a range of cellular responses including; G2M cell cycle 
arrest, autophagy, mitotic catastrophe, caspase-dependent cell 
death and caspase-independent cell death. In this report, we 
Figure 3. CAZ-3 induces autophagy in adenocarcinoma-derived cell lines. Cells were treated with ethanol vehicle [0.2% (v/v)] or 50 nM CAZ-3 ± BAF-A1 
(5 nM). BAF-A1 was added 45 min before the addition of acridine orange. After 48 h, cells were stained with 1 µg/ml acridine orange for 15 min. The dif-
ferential staining of acridine orange can detect the acidic vesicles of autophagic cells. (A) Representative flow cytometry dot plots are shown of acridine orange 
stained CT-26 cells. The acidic vesicles of the autophagic cells (top left and right quadrants) were quantified by FlowJo software. (B) Values represent the 
mean ± SEM for at least three independent experiments (Student's t-test: *P<0.05).
Figure 4. Analysis of the stability of CA-4 and CAZ-3 in plasma and at pH 3.0 over time. Compounds were incubated at 37˚C in plasma pH 7.3 (A) or PBS 
pH 3.0 (B) and aliquots were taken and analysed by HPLC at various time intervals. The percentage recovery was calculated using the formula [(plasma or 
pH 3.0 peak area/mean aqueous peak height) x 100]. The absence of an error bar indicates that the error was smaller than the size of the symbol. Results are 
expressed as the mean ± SEM for three independent experiments (two-way ANOVA with Bonferroni post tests: **P<0.001).
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demonstrate that further substitutions to the aromatic ring at 
position 3 of the azetidinone yielded a superior compound 
with enhanced stability and potency against combretastatin 
refactory adenocarcinoma-derived cells and tumours without 
altering the biological properties of CA-4. The lead compound 
CAZ-3 inhibited the polymerisation of tubulin (9), induced a 
G2M cell cycle arrest and a time-dependent increase in cell 
death (sub-G1) in the colon adenocarcinoma-derived CT-26 
cells in a similar manner to its phosphate prodrug counterpart 
(CAZ-3P) and CA-4. As recently observed with CA-4 (10), 
CAZ-3 also induced autophagy in CT-26 adenocarcinoma 
cells. Autophagy is a highly regulated self-catabolic process 
which can facilitate a prolonged cell survival in spite of 
adverse stress by generating energy via lysosomal degrada-
tion of cytoplasmic constituents (18). Furthermore, we have 
previously demonstrated that manipulation of autophagy can 
enhance the therapeutic potential of CAZ-2 (10).
The adenocarcinoma-derived HT-29 cells are inherently 
resistant to CA-4. The mechanism of innate resistance remains 
undefined. Recent studies rule out multidrug resistance 
protein-1 (MRP-1) mediated resistance to CA-4 in HT-29 
cells (12). MRP-1 is a member of the ATP-binding cassette 
family of polytopic membrane transporters and is responsible 
for conferring resistance to a broad range of chemothera-
peutic drugs (19). However, the authors demonstrate a role 
for MRP-1 in mediating resistance to some oxazole CA-4 
derivatives (12). Data obtained from SARs from numerous 
independent studies on CA-4 analogues provide some insight 
into the possibility of structural modification of CA-4 as a 
means of overcoming CA-4 resistance. In this report we 
demonstrate that a substitution of the ethylene bridge with 
a β-lactam ring (CAZ-1) increased activity in HT-29 cells 
compared to CA-4 by 8-fold. This finding would suggest that 
cis-trans isomerisation is not solely responsible for CA-4 
resistance in HT-29 cells but may contribute in part to CA-4 
resistance in these cells. This mecha nism of resistance may 
be overcome by synthetic analogues featuring an ethylene 
bridge substitution with various types of heterocyclic rings 
yielding stable analogues which do not isomerise. We also 
report that deletion or substitution of the B-ring meta-hydroxy 
group with an amine conjugated amino acid in conjunction 
with introduction of a 3-position aromatic ring significantly 
enhances the activity of the series by up to 300-fold in HT-29 
cells as compared to CA-4. These findings are in agreement 
with a recent report by Schobert et al (12) demonstrating 
improved activity of oxazole bridged CA-4 analogues by 
substitution of the B-ring phenolic group with H, fluoro or 
amino groups. Also, substitution of the ethylene bridge with 
a sulfone group coupled with the substitution of B-ring 
with a 5-amino-6-methoxyquinoline moiety yielded a novel 
compound with activity in the low nanomolar range in HT-29 
cells (IC50=16 nM) (20). Ring B 4-ethoxyphenyl 1,5-diaryl 
substituted 1,2,3,4-tetrazoles also displayed potent activity 
in HT-29 cells (21). Taken together these findings highlight 
the potential of B-ring meta-hydroxy group substitutions 
or deletions in cis-stable analogues of CA-4 as a means of 
overcoming innate resistance to CA-4. However, our lead 
compound CAZ-3, a cis-restricted CA-4 analogue with a 
B-ring meta-hydroxy group demonstrated potent nanomolar 
activity in HT-29 cells. Molecular modelling studies high-
lighted a novel site of interaction between the para-phenolic 
3-position of compound CAZ-3 with the colchicine binding 
site of tubulin (9). This unique tubulin binding characteristic 
is shared with compound CAZ-5 via the B-ring ethoxy group 
but not with CA-4 and the other listed β-lactams (11). The 
additional hydrophobic contact of CAZ-3 and CAZ-5 with 
tubulin may facilitate the observed potent antiproliferative 
effects observed in the CA-4 resistant HT-29 cells and offer a 
novel means of overcoming CA-4 resistance.
Based on promising in vitro data we proceeded to evaluate 
the therapeutic efficacy of CAZ-3 in the mouse CT-26 model 
of colon adenocarcinoma. As a single agent CA-4 failed to 
reduce the growth of CT-26 tumours in vivo (13). Here we 
report that a single injection of CAZ-3 (40 mg/kg) significantly 
inhibited the growth of CT-26 tumours in vivo. Furthermore, 
CAZ-3 reduced the tumour levels to 34% of control untreated 
tumour size. This value is below the T/C value of 42% which 
is defined as the minimum level of activity required by the 
National Cancer Institute criteria. However, despite an excel-
lent tumour response rate, a single i.p. injection of CAZ-3 at 
40 mg/kg gave adverse side effects such as rough coat, loss of 
appetite and diarrhoea along with a mortality rate of 1/5. The 
single maximum tolerated dose for CA-4P was 360 mg/m2 in 
rats and 100 mg/m2 in dogs (22). Serious diarrhoea has been 
reported elsewhere in animals given an i.p. injection of CA-4 
at 100 mg/kg (23). CA-4P (100 mg/kg) had a mortality rate 
of 25% in rats (http://arno.unimaas.nl/show.cgi?fid=7247). 
In 90% of patients CA-4P is well tolerated at 52 mg/m2 (22). 
Given that CAZ-3 is intrinsically more stable than CA-4 and 
has a slower intrinsic clearance time, CAZ-3 may be more 
active in vivo as well as in vitro and thus may require signifi-
cantly lower dosing rates. Optimising the dosing schedule 
and/or administration route may yield more favourable results.
In conclusion, we have presented preclinical data on a novel 
series of cis-stable combretastatin analogues. We demonstrate 
that our lead compound CAZ-3 is effective against CA-4 resis-
tant colon cancer-derived cells in vitro and in vivo. Further 
studies are warranted to characterise the metabolites of CAZ-3 
and optimise dosing schedules with a view to improving the 
therapeutic potential of this novel class of cis-stable vascular 
targeting agents.
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